Featured Research

from universities, journals, and other organizations

Study targets treatment for serious ACE inhibitor side effect, facial, tongue and airway swelling

Date:
April 28, 2011
Source:
Henry Ford Health System
Summary:
A new study takes a closer look at one of the lesser known, but potential most serious side-effects of ACE inhibitor use -- facial, tongue and airway swelling -- and identifies a successful and less invasive course of treatment.

A new Henry Ford Hospital study takes a closer look at one of the lesser known, but potential most serious side-effects of ACE inhibitor use -- facial, tongue and airway swelling -- and identifies a successful and less invasive course of treatment.

Using a treatment protocol developed by Henry Ford, patients' symptoms were quickly diagnosed and promptly treated to reduce swelling, resulting in no tracheotomies to open the airway or reported deaths, says study author Samer Al-Khudari, M.D.

"This side-effect is rare, but when it happens, it can be anxiety-provoking for both patients and physicians," says Dr. Al-Khudari, a member of the Department of Otolaryngology-Head & Neck Surgery at Henry Ford.

"Our goal was to really take a closer look at the treatment options available and develop a better standard of care for not just otolaryngologist, but all health care providers to follow."

The study will presented April 30 at 114th Annual Meeting of the Triological Society, part of the Combined Otolaryngology Spring Meetings in Chicago.

ACE inhibitors are a popular class of drugs most often prescribed to treat high blood pressure, congestive heart failure and kidney disease, as well as prevent stroke.

While they are well-tolerated by most patients, there are some side effects including angiodema, swelling that occurs in areas of the head and neck (floor of mouth, tongue, lips, throat) and can lead to airway obstruction.

Patients most commonly come into the emergency department experiencing difficulty swallowing, shortness of breath and voice changes.

ACE inhibitor induced angiodema (AIIA) tends to be more common among African Americans.

The study included 40 patients who received care at Henry Ford Hospital over a one-year period. The majority of patients (92%) were African American, and most were taking an ACE inhibitor called Lisinopril.

Treatment for all patients at Henry Ford included IV corticosteroids and antihistamines. On average, medical therapy was initiated by otolaryngology services about one hour after the initial evaluation in the emergency department.

All patients underwent a physical examination and laryngoscopy, which uses a flexible viewing tube to evaluate the back of the throat, including the voice box. Floor of mouth swelling was present in 50% of patients, and massive tongue swelling was found in 11.6%.

About half of the patients were admitted to the intensive care unit, while six required intubation and 14 were monitored and discharged from the ER. None of the patients needed emergency tracheotomy or cricothyrotomy for airway control.

Throughout the course of treatment, inpatients were evaluated at least twice a day by the otolaryngology service, and repeat flexible laryngoscopy was performed based on symptoms. Patients were discharged with or without a tapered steroid dose and scheduled for outpatient follow-up.

For most patients, AIIA was resolved in 27 hours.

"If a patient taking an ACE inhibitor notices intermittent swelling in the mouth, lips, face, the medication may very well be the culprit. When this type of swelling occurs, we recommend that patients contact their health care providers immediately and not wait for symptoms to worsen," says Dr. Khudari.

Regardless, Dr. Khudari says it's very important for patients to note that the benefits of ACE inhibitors greatly outweigh the potential risks.

In addition to Dr. Khudari, study authors are Michael J. Loochtan, University of Toledo College of Medicine; and Kathleen L. Yaremchuk, M.D., chair of the Department of Otolaryngology-Head & Neck Surgery at Henry Ford Hospital.


Story Source:

The above story is based on materials provided by Henry Ford Health System. Note: Materials may be edited for content and length.


Cite This Page:

Henry Ford Health System. "Study targets treatment for serious ACE inhibitor side effect, facial, tongue and airway swelling." ScienceDaily. ScienceDaily, 28 April 2011. <www.sciencedaily.com/releases/2011/04/110428101801.htm>.
Henry Ford Health System. (2011, April 28). Study targets treatment for serious ACE inhibitor side effect, facial, tongue and airway swelling. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2011/04/110428101801.htm
Henry Ford Health System. "Study targets treatment for serious ACE inhibitor side effect, facial, tongue and airway swelling." ScienceDaily. www.sciencedaily.com/releases/2011/04/110428101801.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins